Zoxy

Quick links to important sections

Zoxy

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zoxy

What is Zoxy? An Overview of Lornoxicam

Property Description
Active Ingredient Lornoxicam
Forms Oral (Tablet), Parenteral (Injection)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use Symptomatic relief of pain and inflammation
Origin Synthetic Compound (Oxicam derivative)

Core Identity and Classification

Zoxy is a medication defined by its active component, Lornoxicam, and is classified as a potent, synthetic Nonsteroidal Anti-inflammatory Drug (NSAID). Its chemical structure places it within the Oxicam derivative family, distinguished by its thiopyrimidine origin. The classification as an NSAID confirms its primary role in reducing inflammation and providing analgesia without being chemically related to opioids. Lornoxicam's chemical structure and pharmacological action indicate its role in pain management and anti-inflammatory pathways. This confirms that the medication is designed to address discomfort originating from inflammatory responses.

Lornoxicam, the active ingredient in Zoxy, is clinically recognized for its rapid onset of action compared to some older NSAIDs. This characteristic gives Zoxy a specific positioning in the management of conditions requiring prompt symptomatic relief, such as acute musculoskeletal discomfort.

Composition, Forms, and General Purpose

Lornoxicam is consistently manufactured as a single-ingredient product, containing only the active substance alongside necessary pharmaceutical excipients. The medication is prepared in two main forms: the oral formulation (such as a tablet) and the parenteral formulation (a powder for solution for injection), intended for professional administration via the intravenous or intramuscular route of administration.

This dual availability is critical for clinical flexibility. Lornoxicam possesses potent anti-inflammatory and analgesic properties with established efficacy in mitigating both pain and swelling. These properties reinforce the medicine’s primary therapeutic objective: to rapidly and effectively provide symptomatic relief from inflammatory conditions. The overall general purpose of Zoxy is to achieve symptomatic improvement by simultaneously delivering a triple therapeutic benefit: analgesia, anti-inflammation, and an antipyretic effect, positioning it as a tool for managing inflammatory discomfort.

Regulatory References

  1. EMA: Xefo Assessment Report

What side effects are possible with Zoxy?

Possible side effects and safety information

The safety profile of Zoxy, containing Lornoxicam, is classified by regulatory authorities based on adverse reactions reported during clinical development and post-marketing surveillance, consistent with its profile as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Adverse reactions are grouped by the system-organ class affected and assigned a frequency. The most commonly reported adverse events involve Gastrointestinal Disorders, including nausea, dyspepsia (indigestion), abdominal pain, and diarrhoea, as well as Nervous System effects like headache and dizziness. Certain serious events, such as gastrointestinal ulceration and bleeding, are classified as uncommon or rare.

Documented Serious Adverse Reactions

Official labeling highlights specific risks considered serious. These include potentially fatal gastrointestinal bleeding, ulceration, or perforation. Additionally, use may be associated with an increased risk of serious arterial thrombotic events, such as myocardial infarction (heart attack) and stroke. Very rarely, severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS) have been reported, with the highest risk noted early in the course of therapy.

Population-Specific Safety Constraints

Safety notes are explicitly defined for certain groups. The elderly population is documented to have an increased frequency of adverse reactions, particularly the risk of fatal gastrointestinal bleeding. Zoxy is generally contraindicated in individuals with severe impairment of heart, liver, or kidney function. Caution is required in patients with pre-existing heart conditions due to the risk of fluid retention and oedema. Furthermore, the drug may be associated with the impairment of female fertility.

Overdose and Emergency Response

Overdose with Zoxy (Lornoxicam) is officially documented by regulatory agencies and requires immediate medical evaluation. The overdose profile describes initial manifestations that may include common gastrointestinal symptoms such as nausea and vomiting, alongside central nervous system (CNS) effects like dizziness and disturbances in vision. The documentation warns of potential escalation to severe neurological outcomes, including signs such as ataxia, cramps, and progression toward coma.

Beyond CNS effects, serious physiological outcomes are noted, including a change of liver function, a change of kidney function, and the possibility of coagulation disorders. These documented severe risks form the basis for the requirement to seek immediate medical attention for any suspected overdose.

In the event of a real or suspected overdose, the regulatory documents mandate the immediate withdrawal of the medication. Official labeling confirms that no specific antidote for Lornoxicam is known. Consequently, management is structured as entirely symptomatic and supportive treatment. Recommended emergency procedures include considering the use of gastric lavage and activated charcoal to reduce further absorption. Lornoxicam is noted as not dialyzable.

Therapeutic Uses of Zoxy

What Zoxy Treats: Main Uses and Benefits

Zoxy (Lornoxicam) is considered relevant across domains where symptoms related to physical discomfort and inflammatory or irritative states are the primary challenges. The medication is used in contexts involving heightened systemic burden, providing support that may help ease the overall symptom burden.


Chronic and Acute Symptomatic Support

Lornoxicam is commonly used for managing symptoms associated with both chronic inflammatory joint diseases (such as Osteoarthritis and Rheumatoid Arthritis) and acute pain episodes (including post-surgical discomfort and acute sciatica). This is relevant in conditions associated with acute or disruptive episodes, such as when symptoms create noticeable physiological strain.

Comprehensive Symptom Management

Lornoxicam helps address symptom clusters that may become intense or disruptive, covering pain, localized swelling, and associated fever. This support is relevant when short-term symptomatic assistance is needed, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations.


Symptomatic Focus: Relief for Acute Pain and Inflammation

Eligibility and Restrictions for Use

The use of Zoxy (Lornoxicam) is strictly defined by regulatory eligibility criteria, limiting its use primarily to adults who do not have specific contraindications. The medicine is contraindicated and must not be used in numerous populations, most notably those with severe heart failure, severe hepatic impairment, or severe renal impairment (defined by serum creatinine levels above 700 mu mol/L). Absolute prohibitions also apply to patients with active or recurrent peptic ulceration or gastrointestinal bleeding, as well as any known hypersensitivity to Lornoxicam or other Nonsteroidal Anti-inflammatory Drugs.

Age-related rules state that the medicine is not recommended for children and adolescents under 18 years due to insufficient data on efficacy and safety. Use is contraindicated during the third trimester of pregnancy and is not recommended during the first and second trimesters or while breastfeeding.

For populations with existing conditions that are not severe, such as mild to moderate renal or hepatic impairment, use is permitted but requires heightened clinical and laboratory monitoring. Similarly, patients with a history of gastrointestinal disease or uncontrolled hypertension require the medicine to be administered with precaution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns for Zoxy (Lornoxicam), primarily rooted in Pharmacodynamic Reinforcement and Pharmacokinetic Interference.

Contraindicated Combinations and Enhanced Risk

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is officially documented as contraindicated due to the enhanced risk of adverse effects. Lornoxicam may enhance the effects of anticoagulants such as Warfarin, which significantly increases the risk of bleeding. This risk of bleeding is also amplified when co-administered with Antiplatelet agents or Selective Serotonin-Reuptake Inhibitors (SSRIs).

Exposure and Clearance Modification

Lornoxicam is metabolized primarily via CYP2C9 isoenzymes, leading to potential interactions with enzyme inhibitors like Cimetidine, which may result in increased Lornoxicam plasma concentrations. Lornoxicam can also increase the serum concentration and potential toxicity of medicines with narrow therapeutic windows, such as Methotrexate and Lithium, by reducing their renal clearance. Furthermore, combining Lornoxicam with Cyclosporine or Tacrolimus officially elevates the risk of nephrotoxicity.

Effect Antagonism and Timing Rules

Official labeling indicates Lornoxicam may reduce the therapeutic effect of Diuretics (e.g., Furosemide) and certain Antihypertensive agents. Consumption of alcohol is not recommended as it increases the risk of gastrointestinal bleeding. Finally, administration of Activated Charcoal must be separated from Lornoxicam intake, as it may cause diminished absorption.

Mechanism of Action

Core Mechanism: Inhibition of Eicosanoid Pathways

Zoxy, containing Lornoxicam, acts through a dual pharmacodynamic mechanism, initiated by the reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This molecular action prevents the conversion of arachidonic acid into pro-inflammatory prostaglandins and other eicosanoid mediators at the local level. This inhibition leads to a reduction in local inflammatory mediator synthesis and an increase in peripheral nociceptor activation threshold, thereby modulating local physiological responses.

Central Signal Modulation

Beyond peripheral enzyme inhibition, Lornoxicam engages a central mechanism that contributes to its overall physiological activity. This involves the modulation of neurochemical pathways in the Central Nervous System (CNS), associated with increased levels of endogenous opioid peptides (such as dynorphin and beta-endorphin) that modulate central nociceptive transmission. Furthermore, its central COX inhibition suppresses Prostaglandin E2 ( PGE2) synthesis in the hypothalamus, directly leading to modulation of the hypothalamic thermostatic set point.

Dosage and Administration Information

The administration of Zoxy (Lornoxicam) is defined by rules focusing on using the lowest effective dose for the shortest duration necessary to control symptoms.

Administration Routes and Standard Dosing

Zoxy is available for oral use as tablets and as a powder for solution for injection, administered via the Intravenous (IV) or Intramuscular (IM) routes. The total daily dose should not exceed 16 mg across all approved indications.

Usage Context Daily Dose Range Frequency Pattern
General Adult Use (Oral) 8 mg to 16 mg Divided into 2 or 3 doses daily
Chronic Conditions (e.g., RA/OA) Initial 12 mg daily Divided into 2 or 3 doses daily
Parenteral Initiation 8 mg single injection Further 8 mg may be given in the first 24 hours

Contextual and Procedural Requirements

Oral formulations must be taken before meals with a sufficient amount of liquid. This timing is specified to prevent a reduction in the rate and extent of absorption, which is critical for proper use.

The parenteral form requires specific procedural steps: the powder must be immediately reconstituted prior to administration. IV injections should be given over a minimum of 15 seconds, and IM injections over a minimum of 5 seconds.

Population-Specific Use

Administration to children and adolescents under the age of 18 is not recommended due to a lack of data on safety and efficacy. For patients with mild to moderate renal or hepatic impairment, a dose reduction should be considered, often achieved by limiting administration frequency to once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zoxy (Lornoxicam)

Evidence for Use in Acute Pain Management

The clinical research base for Zoxy is primarily built on randomized controlled trials (RCTs). These are studies designed to explore how outcomes related to physical discomfort change over short time intervals. Zoxy was studied for pain that occurs acutely, such as following surgical procedures and in patients experiencing acute or disruptive episodes of low back pain. The research examined measures like the total change in reported pain intensity, the time it took for patients to first report a change in comfort level, and the time until patients requested additional pain relief medication. Findings describe patterns observed in the studies where, in the hours immediately following a procedure, studies monitored changes in these short-term pain measures.

Study Endpoints for Acute Pain Relief

Research has explored various measures to quantify the intensity of pain and the nature of relief. The studies used in research contexts involving fluctuating or unstable symptoms relied on patient-reported outcomes describing perceived discomfort. These include standard scales that track the intensity of pain and specific measurements designed to determine the time until a patient first seeks or needs to take further analgesic medication.


Evidence for Use in Chronic Inflammatory Joint Conditions

This part will overview the research base supporting Zoxy in the symptomatic management of long-term conditions like Osteoarthritis and Rheumatoid Arthritis, highlighting the types of trials used to assess changes in patient function and discomfort. The research program included medium-term randomized controlled trials where Zoxy was observed in patients for periods of several weeks to a few months.

The studies focused on outcomes reflecting daily functioning or activity level and outcomes linked to inflammatory or irritative states. Researchers examined changes in outcomes related to physical discomfort, functional indices like the WOMAC scale, and the patients' own global assessment of their disease state. Studies report how symptoms evolved in the observed populations across multiple measures related to joint pain and stiffness.

Assessing Functional Improvement and Symptom Change

In the context of chronic joint conditions, research examined not only pain scores but also how patients’ ability to perform routine activities changed. The studies were applied in research contexts involving fluctuating or unstable symptoms to determine the change in scores related to walking, climbing stairs, and carrying out daily tasks, as reported by the patients themselves.


Research Evidence in Special Populations and Limitations

Research was evaluated in different patient groups, including specific analyses of older adults with chronic conditions. However, data for certain groups remain insufficient. For instance, Zoxy was not studied for or evaluated in children and adolescents. Therefore, the evidence base for these younger populations is insufficient. Furthermore, long-term effects are not fully established beyond the typical six-month to one-year follow-up periods seen in the chronic disease trials, as follow-up durations were limited in many studies.

Key Studies & References

  1. Summary of Product Characteristics (SPC) - Xefo (Regulatory Document detailing use in children and elderly)

Frequently Asked Questions (FAQ)

Common questions about Zoxy (FAQ)

Q: How long does it usually take for Zoxy to start working?

A: Studies and official information indicate that Zoxy (Lornoxicam) is known for its rapid onset of action. Clinical studies have noted that the initial analgesic effect has been observed to begin within a timeframe of approximately 30 to 60 minutes after administration.

Q: Is Zoxy the same kind of medicine as [similar common drug name]?

A: Zoxy’s active ingredient, Lornoxicam, is classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) of the Oxicam derivative class. Official documents state that taking Zoxy at the same time as other NSAIDs, including COX-2 inhibitors, is contraindicated due to an enhanced risk of adverse effects.

Q: Are there any common over-the-counter pain relievers that interact with Zoxy?

A: Official labeling advises against co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This is because combining these types of medicines, which includes some common over-the-counter pain relievers, is associated with an enhanced risk of serious adverse effects.

Q: What do official guidelines say about Zoxy and kidney function?

A: Regulatory documents state that Zoxy is contraindicated (must not be used) in patients with severe renal impairment (severe kidney issues). For individuals with mild to moderate renal impairment, the official labeling states that the medicine may be used, but requires precaution and consideration of a dose reduction.

Q: What do the official guidelines say about who is eligible for Zoxy?

A: Official guidelines define the eligible population as adults indicated for the symptomatic relief from pain and inflammation. Eligibility strictly excludes patients with any of the official contraindications, such as severe heart, liver, or kidney impairment, or a history of active bleeding or ulceration.

Q: What kind of evidence supports the use of Zoxy?

A: The evidence supporting the use of Zoxy is based on various randomized controlled trials (RCTs). These studies have examined its use for the symptomatic relief of acute pain, as well as the management of chronic inflammatory joint conditions like Osteoarthritis and Rheumatoid Arthritis.

Q: Is Zoxy available without a prescription?

A: Zoxy is classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID). In most regulatory jurisdictions, medications of this type are designated as Prescription-Only Medicines (POM) and are not generally available for purchase over the counter.

Q: What does official documentation say about Zoxy and a history of allergic reactions?

A: Official documentation explicitly states that Zoxy is contraindicated if a patient has a known history of hypersensitivity (allergic reaction) to Lornoxicam or to any other Nonsteroidal Anti-inflammatory Drug (NSAID). This includes allergic-type reactions triggered by other NSAIDs in the past.

Q: What happens if I stop taking Zoxy suddenly?

A: Official documents do not describe specific withdrawal symptoms associated with stopping Zoxy suddenly. Regulatory advice focuses on using the drug for the shortest possible duration, and the labels do not describe specific withdrawal symptoms.

Q: What are the signs that Zoxy might not be working for me?

A: The product is indicated for the symptomatic relief of pain and inflammation. If the drug’s primary therapeutic objective (reduction in discomfort or inflammation) is not achieved, official labels do not provide a checklist of signs of ineffectiveness.

Q: How does Zoxy affect pregnant women or an unborn baby?

A: Zoxy is contraindicated during the third trimester of pregnancy. Official guidelines also state that it is not recommended during the first and second trimesters, or while breastfeeding. This is due to safety concerns and potential risks of fetal heart complications that are associated with NSAID use late in pregnancy.

Q: Why do some people say they felt tired when they first started taking Zoxy?

A: While official documents may not explicitly list tiredness or fatigue as common, other Nervous System side effects such as dizziness or mild headache are commonly reported adverse events. This information is based on adverse event reporting.

Q: Can Zoxy affect my sleep schedule?

A: Adverse reaction reporting documents occasionally list disturbances such as insomnia (difficulty sleeping) and somnolence (drowsiness) among the documented side effects of Lornoxicam. These effects, though not always common, have been reported.

Q: Is it normal to feel a mild headache when starting Zoxy?

A: Official adverse reaction reporting classifies headache as a common side effect of Zoxy (Lornoxicam). This is a known, possible effect reported in clinical trials, particularly during the initial phase of administration.

Q: Why do some doctors choose Zoxy over other treatments?

A: Official documents describe Zoxy (Lornoxicam) as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) that demonstrates analgesic, anti-inflammatory, and fever-reducing properties. Its specific pharmaceutical properties include a clinically recognized rapid onset of action, which can influence its selection for acute pain management.

Q: Does Zoxy have a risk of dependence or addiction?

A: Zoxy’s active ingredient, Lornoxicam, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not chemically related to opioid medications. Official regulatory documents and clinical profiles do not indicate a risk of drug dependence or addiction associated with its use.

Q: Does Zoxy cause weight changes?

A: Official side effect reports do not list weight change as a common adverse event. However, Zoxy, like other NSAIDs, may be associated with fluid retention and oedema (swelling), which may be observed by patients as a temporary change in body weight.

Q: What is the official guidance on driving or operating machinery while taking Zoxy?

A: Official documentation states that if a patient experiences adverse effects such as dizziness or vision disturbance, they are advised not to drive or operate machinery. This caution is based on the potential for these side effects to affect coordination or concentration.

Q: What is the difference between Zoxy and its generic version?

A: Generic versions contain the identical active ingredient, Lornoxicam. Regulatory bodies require generic products to demonstrate bioequivalence to the brand-name product. This means they are proven to deliver the same amount of the active substance into the bloodstream in the same time frame.

Q: What does the research say about Zoxy’s effectiveness compared to a placebo?

A: Clinical trials utilized to gain regulatory approval confirm that Zoxy (Lornoxicam) provides analgesic (pain-relieving) and anti-inflammatory effects that are superior to placebo. This effectiveness has been demonstrated across measures of acute pain relief and symptomatic improvement in chronic inflammatory conditions.

Q: Does Zoxy interact with herbal teas or remedies?

A: Official documents do not list specific herbal products. However, because Zoxy interacts with drugs affecting clotting and is metabolized by certain liver enzymes (CYP2C9), the product information indicates a need for caution with herbal remedies that may affect these physiological systems.

Q: Can Zoxy be taken with alcohol?

A: Official documentation states that the use of Zoxy in combination with alcohol is discouraged, as this combination increases the risk of serious adverse effects, particularly gastrointestinal bleeding.

Q: Is it possible to be allergic to Zoxy?

A: Yes. Official labeling classifies the use of Zoxy as contraindicated in any patient with a known hypersensitivity (allergic reaction) to Lornoxicam or any of the inactive ingredients, as well as to other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Q: How is Zoxy typically packaged?

A: Zoxy is manufactured in two main pharmaceutical forms according to official documentation: oral tablets are typically supplied in blister packs, and the parenteral form is supplied as a powder for solution for injection in glass vials that require reconstitution.

Q: Does Zoxy contain any gluten or common allergens?

A: The official product information provides a complete list of inactive ingredients (excipients). While the specific presence of common allergens like gluten must be verified against the specific product’s excipient information, patients with known sensitivities to components like lactose are advised to review the official list.

Q: Can Zoxy cause changes in mood or behavior?

A: Official reports of adverse events include rare Nervous System and Psychiatric disorders. These can encompass documented events such as depression, confusion, agitation, or nervousness, which reflect changes in mood or behavior.

Q: Can older adults generally take Zoxy?

A: Official documents indicate that Zoxy can be administered to older adults. However, this population is documented to have an increased frequency of adverse reactions, especially gastrointestinal bleeding, meaning its administration requires precaution and medical monitoring may be necessary.

How should Zoxy be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and disposing of Zoxy to maintain its stability and effectiveness.

Storage Component Official Requirement
Temperature Store at or below the temperature specified on the label, typically 25 C or 30 C.
Protection Keep the medicine in its original container to protect it from light and moisture. Do not freeze the product.
Stability Do not use the medicine past the expiration date. If applicable, discard the product after a specified 'in-use' period following opening or reconstitution.
Child Safety Keep Zoxy out of the reach and sight of children at all times.
Disposal Do not flush unused or expired Zoxy down a toilet or pour it down a drain unless specifically instructed by the regulatory label. Follow official instructions by utilizing a drug take-back program or preparing the medicine for household trash disposal as specified by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zoxy found in:

A-Z Index: